- Report
- March 2024
- 190 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- March 2024
- 182 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- April 2024
- 193 Pages
Global
From €4778EUR$4,950USD£4,098GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Report
- October 2023
- 190 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- June 2020
- 113 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- August 2022
- 118 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Drug Pipelines
- August 2020
- 59 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- May 2023
- 90 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Drug Pipelines
- June 2021
- 62 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- February 2024
- 206 Pages
Global
From €3475EUR$3,600USD£2,981GBP
Cryptococcosis is a fungal infection caused by the Cryptococcus neoformans and Cryptococcus gattii species. It is a serious infection that can affect the lungs, central nervous system, and other organs. Treatment of cryptococcosis typically involves antifungal medications, such as amphotericin B, fluconazole, and voriconazole. These drugs are used to treat both cryptococcal meningitis and cryptococcal pneumonia.
The cryptococcosis drug market is a subset of the infectious diseases drug market. It is composed of antifungal medications used to treat cryptococcosis. These drugs are used to treat both cryptococcal meningitis and cryptococcal pneumonia.
Some companies in the cryptococcosis drug market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more
